GlassScriptPhysician profile
Nadine P Ramdeen Wright
NPI 1558453308
$1,980.51
in general payments reported to CMS, 2019-2025
25 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $242 · 2021: $229 · 2022: $272 · 2023: $238 · 2024: $523 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.46 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291.41 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $242.43 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $224.01 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $205.71 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Amarin Pharma, INC. | $181.38 | 2019-2021 | |
| Abbott Laboratories | $124.43 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $96.30 | 2021-2024 | Otezla, Repatha |
| Corcept Therapeutics | $65.96 | 2025 | Korlym |
| Astellas Pharma US INC | $64.99 | 2024 | |
| Gilead Sciences, INC. | $55.10 | 2020-2021 | |
| Pfizer INC. | $46.63 | 2024-2025 | |
| Viiv Healthcare Company | $40.69 | 2024 | Apretude |
| Exact Sciences Corporation | $40.38 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Avvisto Therapeutics, LLC | $37.85 | 2024-2025 | Cycloset |
| Teva Pharmaceuticals USA, INC. | $37.52 | 2019-2025 | Ajovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.93 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $34.82 | 2022 | |
| Sanofi Pasteur INC. | $28.93 | 2019-2021 | |
| Phadia US INC. | $23.86 | 2024 | Immunocap |
| Boston Scientific Corporation | $20.17 | 2025 | Watchman Flx |
| Lilly USA, LLC | $19.05 | 2022 | |
| Abbvie INC. | $18.03 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.37 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.60 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $12.96 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadine Ramdeen Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.